Experimental drug duo targets Hard-to-Treat cancers

NCT ID NCT04007744

Ongoing Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the safest dose and see if the combination can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sonidegib and pembrolizumab
What this could lead to: If it works, this combination could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early, small Phase 1 trial focused on safety and dosing, not proof of effectiveness. The combination may cause significant side effects and may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer cutaneous melanoma gastric adenocarcinoma gastric cancer gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma lung neoplasm melanoma metastatic malignant neoplasm metastatic melanoma Neoplasm Metastasis non-small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 CLINICAL STAGE III GASTRIC CANCER AJCC V8 CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 CLINICAL STAGE IV GASTRIC CANCER AJCC V8 CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 LOCALLY ADVANCED GASTRIC ADENOCARCINOMA LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA LOCALLY ADVANCED UROTHELIAL CARCINOMA METASTATIC GASTRIC ADENOCARCINOMA METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA METASTATIC LUNG NON-SMALL CELL CARCINOMA METASTATIC MALIGNANT SOLID NEOPLASM METASTATIC MELANOMA METASTATIC UROTHELIAL CARCINOMA RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA REFRACTORY LUNG NON-SMALL CELL CARCINOMA STAGE IV CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8 STAGE IV LUNG CANCER AJCC V8 UNRESECTABLE MALIGNANT SOLID NEOPLASM UNRESECTABLE MELANOMA

Experimental drug duo targets Hard-to-Treat cancers

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions